- Home
- INSW vs SCLXW Comparison
INSW vs SCLXW Comparison
Compare INSW & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSW
- SCLXW
- Stock Information
- Founded
- INSW 1999
- SCLXW N/A
- Country
- INSW United States
- SCLXW United States
- Employees
- INSW N/A
- SCLXW 113
- Industry
- INSW Semiconductors
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- INSW Technology
- SCLXW Health Care
- Exchange
- INSW Nasdaq
- SCLXW Nasdaq
- Market Cap
- INSW 2.1B
- SCLXW N/A
- IPO Year
- INSW N/A
- SCLXW 2021
- Fundamental
- Price
- INSW $32.54
- SCLXW $0.22
- Analyst Decision
- INSW Strong Buy
- SCLXW
- Analyst Count
- INSW 3
- SCLXW 0
- Target Price
- INSW $60.67
- SCLXW N/A
- AVG Volume (30 Days)
- INSW 723.1K
- SCLXW N/A
- Earning Date
- INSW 11-07-2024
- SCLXW N/A
- Dividend Yield
- INSW 17.74%
- SCLXW N/A
- EPS Growth
- INSW N/A
- SCLXW N/A
- EPS
- INSW 10.33
- SCLXW N/A
- Revenue
- INSW $1,007,734,000.00
- SCLXW N/A
- Revenue This Year
- INSW N/A
- SCLXW N/A
- Revenue Next Year
- INSW $1.61
- SCLXW N/A
- P/E Ratio
- INSW $3.15
- SCLXW N/A
- Revenue Growth
- INSW N/A
- SCLXW N/A
- 52 Week Low
- INSW $32.11
- SCLXW N/A
- 52 Week High
- INSW $65.94
- SCLXW N/A
- Technical
- Relative Strength Index (RSI)
- INSW 18.30
- SCLXW N/A
- Support Level
- INSW $32.73
- SCLXW N/A
- Resistance Level
- INSW $34.22
- SCLXW N/A
- Average True Range (ATR)
- INSW 1.11
- SCLXW 0.00
- MACD
- INSW -0.26
- SCLXW 0.00
- Stochastic Oscillator
- INSW 5.51
- SCLXW 0.00
About INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.